Buffett on Stepping Down as CEO: Time Flies, But Still Sharp in the Face of Market Panic
Berkshire Hathaway Chairman and CEO Warren Buffett stated in an interview with the Wall Street Journal: "For some reason, I didn't really start to feel old until I was around 90, but once you start aging, the change is irreversible." It is reported that Buffett's body has occasionally started to lose balance, and sometimes he finds it difficult to remember people's names. Buffett said, "True talent is very rare, rare in business, rare in capital allocation, and rare in almost all human activities. Honestly, it would be unfair not to put Abel in this position (CEO), and the longer Berkshire benefits from Abel, the better." Buffett praised Abel as both a manager and a dealmaker: "The difference in energy levels and the amount of work completed within 10 hours on a workday between him and me is becoming more apparent. He is more efficient in completing tasks, managing adjustments, and helping those in need." Buffett admitted that aging has weakened some of his abilities, but he stated that he still possesses perhaps the most precious and rare talent as an investor: "I have no difficulty making decisions, whether it's something I decided 20 years ago, 40 years ago, or 60 years ago. If the market panics, I can still be of use because I am not afraid when prices drop or others panic, and that really has nothing to do with age." Recently, Berkshire's massive cash and treasury reserves have been increasing, drawing attention from the outside world, with people wondering where the company will trade next. Buffett said, "Abel will have ideas about where the funds should be directed."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly

XRP Ledger adds account control feature, enabling enterprises to manage assets offline.

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
